Dendreon Sells Royalty Interest

Dendreon Corporation has agreed to sell for $125 million in cash its royalty interest related to intellectual property licensed to Schering and associated with VICTRELIS, a treatment for chronic hepatitis C. The royalty interest was acquired by CPPIB Credit Investments, a wholly-owned subsidiary of CPP Investment Board. PRESS RELEASE Dendreon Corporation today announced that it […]

PEHUB Community

Join the 12501 members of peHUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

Psst! Got any hot tips?

  • This field is for validation purposes and should be left unchanged.

PE HUB News Briefs

RSS Feed Widget

Marketplace

VCJ Headlines (subscribers only)

RSS Feed Widget

Buyouts Headlines (subscribers only)

RSS Feed Widget

Reuters VC and PE feed

RSS Feed Widget